Abstract | OBJECTIVES: BACKGROUND:
Antiarrhythmic drugs are important in protecting against ventricular arrhythmias in ARVC, but no studies have provided data in a group rigorously screened for the disease. METHODS: Antiarrhythmic medicines were examined in all subjects with implantable cardioverter-defibrillators (ICDs) enrolled in the North American ARVC Registry. A Cox proportional hazards model was used to account for time on each drug, and a hierarchical analysis was performed for repeated measures within individuals. RESULTS: Ninety-five patients were studied, with a mean follow-up of 480 +/- 389 days. Fifty-eight (61%) received beta-blockers, and these medicines were not associated with an increased or decreased risk of ventricular arrhythmias. Sotalol was associated with a greater risk of any clinically relevant ventricular arrhythmia as defined by sustained ventricular tachycardia or ICD therapy (hazard ratio [HR]: 2.55, 95% confidence interval [CI]: 1.02 to 6.39, p = 0.045), but this was not statistically significant after adjusting for potential confounders. An increased risk of any ICD shock and first clinically relevant ventricular arrhythmia while on sotalol remained significant after multivariable adjustment. Those on amiodarone (n = 10) had a significantly lower risk of any clinically relevant ventricular arrhythmia (HR: 0.25, 95% CI: 0.07 to 0.95, p = 0.041), a finding that remained significant after multivariable adjustment. CONCLUSIONS: In a cohort of well-characterized ARVC subjects, neither beta-blockers nor sotalol seemed to be protective. Evidence from a small number of patients suggests that amiodarone has superior efficacy in preventing ventricular arrhythmias.
|
Authors | Gregory M Marcus, David V Glidden, Bronislava Polonsky, Wojciech Zareba, Lisa M Smith, David S Cannom, N A Mark Estes 3rd, Frank Marcus, Melvin M Scheinman, Multidisciplinary Study of Right Ventricular Dysplasia Investigators |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 54
Issue 7
Pg. 609-15
(Aug 11 2009)
ISSN: 1558-3597 [Electronic] United States |
PMID | 19660690
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic beta-Antagonists
- Anti-Arrhythmia Agents
- Sotalol
- Amiodarone
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Adult
- Amiodarone
(therapeutic use)
- Anti-Arrhythmia Agents
(therapeutic use)
- Arrhythmogenic Right Ventricular Dysplasia
(complications, therapy)
- Combined Modality Therapy
- Defibrillators, Implantable
- Female
- Humans
- Male
- Middle Aged
- Proportional Hazards Models
- Registries
- Sotalol
(therapeutic use)
- Tachycardia, Ventricular
(etiology, prevention & control)
- Treatment Outcome
- Ventricular Fibrillation
(etiology, prevention & control)
|